BPC-157 oral vs. subcutaneous: is the 'no difference' claim supported?

What did @drdrewtimmermans actually say?

The claim is straightforward: "most patients are going to do about just about the exact same with oral versus injectable." He also pushes back on localized injection protocols, arguing you don't need to inject near the injury site because BPC-157 "is going to end up having its effect systemically" regardless of where you put it. Belly fat, shoulder fat, butt fat, he says, it all reaches circulation the same way.

That's two distinct claims worth separating. First, that oral and subcutaneous BPC-157 produce equivalent outcomes in humans. Second, that systemic absorption makes localized injection irrelevant. Both sound reasonable on the surface. Neither is as settled as the confidence in the video suggests.

Does the science back this up?

Partially, but the human data is nearly nonexistent, and that gap matters enormously here.

The animal literature on oral BPC-157 is actually more interesting than most peptide skeptics admit. Studies in rats, including work by Sikiric et al. published repeatedly in Current Pharmaceutical Design (2018) and Journal of Physiology-Paris (2006), show that orally administered BPC-157 produces measurable effects on gastric ulcer healing, tendon repair, and even systemic inflammation markers. The peptide appears unusually resistant to gastric acid degradation compared to most peptides, which is the theoretical basis for why oral dosing might work at all.

But resistant to degradation is not the same as bioequivalent. No peer-reviewed pharmacokinetic study in humans has directly compared oral versus subcutaneous BPC-157 plasma levels or clinical outcomes. The claim that "most patients" do equally well either way is not supported by clinical trial data. It may reflect clinical observation from a practice, but that's anecdote dressed as equivalence data.

What did they get wrong (or right)?

He gets partial credit on systemic distribution. The idea that subcutaneous injection site doesn't need to be near the injury is broadly consistent with how subcutaneous absorption works. BPC-157 injected into belly fat enters systemic circulation, and there is no strong evidence that perilesional injection produces meaningfully superior outcomes compared to remote subcutaneous sites. Krivic et al. (2008, Journal of Orthopaedic Research) showed tendon healing effects in rats from systemic administration, not localized delivery.

Where he oversimplifies: oral bioavailability of BPC-157 in humans is genuinely unknown. The rat stomach is not a human stomach. Saying "most patients do about just about the exact same" implies he has comparative outcome data. He doesn't cite any, and the published record doesn't provide it either. That's a confident claim built on a shaky foundation.

• Oral stability in rats: supported by multiple Sikiric lab publications
• Human oral bioavailability: no published pharmacokinetic data
• Systemic vs. localized subcutaneous injection: animal data leans toward systemic being sufficient
• Clinical equivalence in humans: unverified

What should you actually know?

BPC-157 is not FDA-approved for any indication. It is used in research and, increasingly, compounded by telehealth platforms, but it has completed no Phase 3 human trials as of this writing. That context belongs in any discussion of route of administration, and it's absent here.

The oral-versus-injectable question is genuinely interesting science, not settled science. If you're considering BPC-157 through a regulated platform, route of administration should be a conversation with a licensed clinician who has reviewed your specific situation, not a TikTok equivalency claim. The fact that oral dosing might work is plausible based on preclinical data. The fact that it works equally well as subcutaneous in humans is an assumption, not a finding.

One more thing worth flagging: injectable peptides carry infection risks that oral forms don't. Even if efficacy were equivalent, that's a clinically relevant difference the video doesn't mention.

The bottom line

This video is not reckless, but it presents a reasonable hypothesis as established clinical fact. The systemic distribution point holds up reasonably well. The oral-versus-injectable equivalence claim is getting ahead of the available human evidence. Watch creators who cite studies, not just vibes from their patient panel.